INTRODUCTION
============

Potassium Clavulanate (PC) is chemically known as Potassium (Z)-(2R, 5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo \[3.2.0\]-heptene-2-carboxylate \[C~8~H~8~KNO~5~, CAS No: 61177-45-5, MW.237.3\] (Figure [1](#F1){ref-type="fig"}). Amoxicillin Trihydrate (AT) is (2S, 5R, 6R)-6-\[(R)-(−)-2-Amino-2-(p-hydroxyphenyl) acetamido\]-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo\[3.2.0\] heptane-2-carboxylic acid trihydrate \[C~16~H~19~N~3~O~5~S•3H~2~O, CAS No: 61336-70-7, MW. 419.46\] (Figure [2](#F2){ref-type="fig"}).

![Structure of Potassium Clavulanate.](IJBS-06-335-g001){#F1}

![Structure of Amoxiclllin Trihydrate.](IJBS-06-335-g002){#F2}

Amoxicillin Trihydrate is semisynthethic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. AT is, however susceptible to degradation by β-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a β-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range of β-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins.

PC and AT are well absorbed from the gastrointestinal tract after oral administration of amoxicillin and potassium clavulanate. Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While PC and AT can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. The relative bioavailability of clavulanate was reduced when PC and AT was dosed at 30 and 150 minutes after the start of high-fat breakfast. The safety and efficacy of PC and AT have been established in clinical trials where PC and AT was taken without regard to meals. The use of potassium clavulanate with penicillins has been associated with an increased incidence of cholestatic jaundice and acute hepatitis during therapy, particularly in men and those aged over 65 years.

The official methods ([@R1], [@R2]) were developed for the determination of PC and AT individually in its pure form but there are some analytical methods ([@R3]-[@R7]) developed for the quantitation of amoxicillin-clavulanate dosage forms.

This paper reports a simple, sensitive and accurate Spectrophotometric method for the simultaneous determination of potassium clavulanate and amoxicillin trihydrate. This method is based on the direct measurement of native absorbance of the drug at 205 and 271 nm against the reagent blank respectively for potassium clavulanate and amoxicillin trihydrate.

EXPERIMENTAL
============

Apparatus
---------

Spectral runs were made on UV 3000^+^ UV/VIS spectrophotometer (LABINDIA^®^, Mumbai, India) with 1 cm matched glass cell.

Materials and Reagents
----------------------

Potassium Clavulanate (Vardhman Life Sciences Pvt. Ltd, Tamilnadu, India) was used as working standard.Amoxicillin Trihydrate (Vardhman Chemtech Ltd, Punjab, India) was used as working Standard.Pharmaceutical formulations of such as Augmentin 625 (GlaxoSmithKline, Mumbai, India), Flemiclav 625 (Vapi Care Pharma Pvt. Ltd, Solan, India), Moxikind-CV 625 (Mankind Pharma Ltd, New Delhi, India) and Clavam 625 (Alkem Laboratories Ltd, Mumbai, India) were purchased from local markets.Sodium carbonate was purchased from Qualigens fine chemicals (Mumbai, India).Sodium bicarbonate was purchased from Qualigens fine chemicals (Mumbai, India).Urine samples were obtained from healthy volunteers.Carbonate buffer of pH 9.4 was prepared by dissolving 26.5 gm sodium carbonate and 21.0 gm sodium bicarbonate in 500 ml distilled water.

Determination of appropriate UV wavelength
------------------------------------------

A suitable wavelength was required for simultaneous determination of PC and AT. The appropriate wavelength for the determination of PC and AT was determined by wavelength scanning over the range 190--500 nm with a UV 3000^+^ UV/VIS spectrophotometer (LABINDIA^®^, Mumbai, India).

Standard PC and AT Solution
---------------------------

A stock solution of PC (50 μg/ml) and AT (100 μ/ml) was prepared by dissolving 5 and 10 mg PC and AT respectively in 100 ml volumetric flasks with double distilled water. The stock solutions were used to prepare the working solutions by suitable dilutions with distilled water. The solutions were stable at least 10 days in room temperature.

METHODS
=======

Procedure for the determination of PC and AT
--------------------------------------------

Aliquots of stock solution 50 μg/ml and 100 μg/ml were transferred into a set of 50 ml volumetric flasks and volumes were completed to the mark with distilled water to produce solutions in the concentration range 0.2--8.5 and 6.4--33.6 μg/ml for PC and AT. Absorbance was measured at 205 and 271 nm respectively for PC and AT against the reagent blank. Calibration graphs were constructed by plotting absorbance against the final concentration of PC and AT.

Procedure for determination of PC and AT in pharmaceutical formulations
-----------------------------------------------------------------------

One tablet (claiming 625 mg) was accurately weighed and finely powdered. A quantity of the powder equivalent to 125 mg of PC and 500 mg AT was extracted by shaking with 50 ml of distilled water, followed by another two extractions each with 50 ml distilled water. After passing through a 0.45 μm Millipore filter, the solution was diluted with distilled water to obtain a concentration of about 1250 and 5000 μg/ml respectively for PC and AT. It was further diluted according to the need and then analyzed following the proposed procedures. The nominal content of the tablet was calculated either from the previously plotted calibration graphs or using regression equation.

Procedure for determination of PC and AT in human urine samples
---------------------------------------------------------------

Aliquot volumes of human urine samples were transferred into small separating funnel. 20 ml of carbonate buffer pH9.4 was added and solution was mixed well. The solution was then extracted with 3 × 20 ml diethyl ether. The ether extract was collected and evaporated. The residue was dissolved in 10 ml distilled water and above general procedure was then followed. The amount of PC and AT was obtained from the calibration graphs or corresponding regression equation.

METHOD VALIDATION
=================

The method was validated for selectivity, linearity, precision, accuracy, recovery and stability according to the principles of the Food and Drug Administration (FDA) industry guidance ([@R8]). Validation of analytical procedures is a vital aspect not just for regulatory purposes, but also for their efficient and reliable long--term application. The ICH guidelines achieved a great deal in harmonizing the definitions of required validation parameters, their calculation and interpretation. It is the responsibility of the analyst to identify parameters which are relevant to the performance of given analytical procedure as well as to design proper validation protocols including acceptance criteria and to perform an appropriate evaluation. The International Conference on the Harmonization of the Technical Requirements for Registration of Pharmaceuticals for Human Use has harmonized the requirements in two guidelines ([@R9], [@R10]). The first one summarizes and defines the validation characteristics needed for various types of test procedures, the second one extends the previous test to include the experimental data required and some statistical interpretation. These guidelines serve as a basis worldwide both for regulatory authorities and industry and bring the importance of a proper validation to the attention of all those involved in the process of submission. Nowadays, the validation characteristics needed for the various test procedures and their general requirements are well understood. The essential question to be answered is on the suitability of the calibration mode to be used in the test procedure. It should be noted that in most cases only a qualitative statement is needed.

The stability of the working sample solutions at room temperature was evaluated with the help of UV spectra. The specificity and selectivity of the proposed method was evaluated by estimating the amount of PC and AT in the presence of common excipients colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, polydextrose, titanium dioxide.

The linearity of the proposed method was constructed for PC and AT reference standard solution by plotting concentration of the compound versus the absorbance. The linearity was evaluated by linear regression analysis, which was calculated by the least square regression method. The parameters LOD and LOQ were determined on the basis of response and slope of the regression equation. The accuracy and precision of the method was evaluated within the linear range based on the analysis of PC and AT reference standard samples and pharmaceutical formulations at 2.0, 5.0, 8.0 and 8.0, 20.0 and 32.0 μg/ml. Five independent analysis were performed at each concentrations level within one day (intraday precision) as well as for five consecutive days (interday precision). The accuracy was ascertained by recovery studies using the standard addition method. The proposed method was used for estimation of PC and AT from tablet after spiking with 50, 150, 250 % and 100, 300, 500 % of additional pure drug. The amount of PC and AT was determined from the regression equation.

RESULTS AND DISCUSSIONS
=======================

The absorbance-concentration plot for the proposed method was found to be rectilinear over the range of 0.2--8.5 and 6.4--33.6 μg/ml respectively for PC and AT. Linear regression analysis of calibration data gave the regression equation cited in Table [1](#T1){ref-type="table"} with correlation coefficients close to unity.

###### 

Summary of optical and regression characteristics of the proposed method

  Parameters                                              Potassium Clavulanate   Amoxicillin Trihydrate
  ------------------------------------------------------- ----------------------- ------------------------
                                                                                  
    Linear dynamic range (μg/ml)                          0.2--8.5                6.4--33.6
    Regression equation[a](#T1FN1){ref-type="table-fn"}   Y=0.0575X--0.003        Y=0.0174X--0.0254
    Slope                                                 0.0575                  0.0174
    Intercept                                             0.003                   0.0254
    Correlation coefficient (r)                           0.9984                  0.9964

With respect to Y = a + b *X*, where X is the concentration in μg/ml, Y is Absorbance.

The within day precision assays were carried out through replicate analysis (n=5) of PC and AT corresponding to 2.0, 5.0, 8.0 and 8.0, 20.0, 32.0 μg/ml respectively for PC and AT. The interday precision was evaluated through replicate analysis of the pure drug samples for five consecutive days at the same concentration levels as used in within day precision. The results of these assays are reported in Table [2](#T2){ref-type="table"}. As can be seen from Table [2](#T2){ref-type="table"} that the recovery and RSD values for within day precision were in the range of 99.826--99.957%, 99.856--100.036% and 0.358--0.954%, 0.098--0.394% respectively for PC and AT; recovery and RSD values for interday precision were in the range of 99.757--100.174%, 99.785--99.828 % and 0.424--1.132%, 0.353--0.644% respectively for PC and AT. The precision results are satisfactory. The intraday and interday precision assays were also carried for PC and AT in pharmaceutical formulations. The results are summarized in Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. As can be seen from Table [3](#T3){ref-type="table"} that the recovery and RSD values for intraday precision were in the ranges 99.269--99.980%; 0.420--1.326%, recovery and RSD values for interday precision were in the ranges 98.783--99.826% ; 0.512--1.566 % for Potassium Clavulanate.

###### 

Summary of accuracy and precision results of the proposed method in pure form

  Proposed methods         Amount (μg/ml)   RSD             REC.      SAE [b](#T2FN2){ref-type="table-fn"}   C.L.[c](#T2FN3){ref-type="table-fn"}   
  ------------------------ ---------------- --------------- --------- -------------------------------------- -------------------------------------- --------------
                                                                                                                                                    
  Potassium Clavulanate                                                                                                                             
  Intraday assay           2.00             1.997 ± 0.019   0.954     99.826                                 8.5 × 10^−3^                           2.4 × 10^−2^
  5.00                     4.991 ± 0.028    0.551           99.826    1.2 × 10^−2^                           3.4 × 10^−2^                           
  8.00                     7.997 ± 0.029    0.358           99.957    1.3 × 10^−2^                           3.6 × 10^−2^                           
  Interday assay           2.00             2.004 ± 0.023   1.132     100.174                                1.0 × 10^−2^                           2.8 × 10^−2^
  5.00                     4.988 ± 0.024    0.671           99.757    1.5 × 10^−2^                           4.2 × 10^−2^                           
  8.00                     7.993 ± 0.034    0.424           99.913    1.5 × 10^−2^                           4.2 × 10^−2^                           
  Amoxicillin Trihydrate                                                                                                                            
  Intraday assay           8.00             7.989 ± 0.032   0.394     99.856                                 1.4 × 10^−2^                           3.9 × 10^−2^
  20.00                    19.989 ± 0.031   0.158           99.943    1.4 × 10^−2^                           3.9 × 10^−2^                           
  32.00                    32.012 ± 0.032   0.098           100.036   1.4 × 10^−2^                           3.9 × 10^−2^                           
  Inter day assay          8.00             7.977 ± 0.051   0.644     99.713                                 2.3 × 10^−2^                           6.4 × 10^−2^
  20.00                    19.965 ± 0.070   0.353           99.828    3.1 × 10^−2^                           8.7 × 10^−2^                           
  32.00                    31.931 ± 0.125   0.390           99.785    5.6 × 10^−2^                           1.6 × 10^−1^                           

Mean for 5 independent analyses.

SD, standard deviation, RSD, relative standard deviation;

SAE, standard analytical error;

C.L., confidence limit at 95 % confidence level and 4 degrees of freedom (t=2.776).

###### 

Summary of accuracy and precision results of the proposed method for Potassium Clavulanate pharmaceutical formulations

  Proposed methods       Amount (μg/ml)   RSD             REC.    SAE [b](#T3FN2){ref-type="table-fn"}   C.L. [c](#T3FN3){ref-type="table-fn"}   
  ---------------------- ---------------- --------------- ------- -------------------------------------- --------------------------------------- --------
                                                                                                                                                 
  Intra day assay                                                                                                                                
    Augmentin -- 625     2.00             1.986 ± 0.019   0.959   99.304                                 0.0085                                  0.0237
    Augmentin -- 625     5.00             4.974 ± 0.035   0.699   99.478                                 0.0156                                  0.0432
    Augmentin -- 625     8.00             7.986 ± 0.042   0.520   99.826                                 0.0186                                  0.0515
    Flemiclav -- 625     2.00             1.990 ± 0.016   0.782   99.980                                 0.0070                                  0.0193
    Flemiclav -- 625     5.00             4.970 ± 0.029   0.575   99.409                                 0.0128                                  0.0355
    Flemiclav --625      8.00             7.983 ± 0.048   0.597   99.783                                 0.0213                                  0.0591
    Moxikind -- CV 625   2.00             1.993 ± 0.023   1.171   99.652                                 0.0104                                  0.0290
    Moxikind -- CV 625   5.00             4.967 ± 0.026   0.531   99.339                                 0.0118                                  0.0327
    Moxikind -- CV 625   8.00             7.979 ± 0.045   0.564   99.739                                 0.0201                                  0.0559
    Clavam -- 625        2.00             1.989 ± 0.027   1.326   99.478                                 0.0118                                  0.0327
    Clavam -- 625        5.00             4.963 ± 0.026   0.531   99.269                                 0.0118                                  0.0327
    Clavam -- 625        8.00             7.969 ± 0.033   0.420   99.609                                 0.0150                                  0.0415
  Inter day assay                                                                                                                                
    Augmentin -- 625     2.00             1.997 ± 0.023   1.136   99.826                                 0.0101                                  0.0281
    Augmentin -- 625     5.00             4.964 ± 0.036   0.727   99.270                                 0.0161                                  0.0448
    Augmentin -- 625     8.00             7.979 ± 0.048   0.605   99.739                                 0.0216                                  0.0599
    Flemiclav -- 625     2.00             1.983 ± 0.025   1.241   99.130                                 0.0101                                  0.0305
    Flemiclav -- 625     5.00             4.967 ± 0.034   0.683   99.339                                 0.0152                                  0.0421
    Flemiclav -- 625     8.00             7.976 ± 0.061   0.765   99.695                                 0.0273                                  0.0757
    Moxikind -- CV 625   2.00             1.986 ± 0.031   1.566   99.304                                 0.0139                                  0.0386
    Moxikind -- CV 625   5.00             4.960 ± 0.038   0.760   99.200                                 0.0169                                  0.0468
    Moxikind -- CV 625   8.00             7.972 ± 0.059   0.733   99.652                                 0.0262                                  0.0726
    Clavam -- 625        2.00             1.986 ± 0.019   0.959   99.304                                 0.0085                                  0.0237
    Clavam -- 625        5.00             4.939 ± 0.030   0.610   98.783                                 0.0135                                  0.0374
    Clavam -- 625        8.00             7.965 ± 0.041   0.512   99.565                                 0.0182                                  0.0506

Mean for 5 independent analyses; RSD, relative standard deviation;

SAE, standard analytical error;

C.L., confidence limit at 95 % confidence level and 4 degrees of freedom (t=2.776).

As can be seen from Table [4](#T4){ref-type="table"} that the recovery and RSD values for intraday precision were in the ranges 99.707--99.820%; 0.327--0.891%, recovery and RSD values for interday precision were in the ranges 98.994--99.713%; 0.424--1.101% for Amoxicillin Trihydrate.

###### 

Summary of accuracy and precision results of the proposed method for Amoxicillin Trihydrate pharmaceutical formulations

  Proposed methods       Amount (μg/ml)   RSD              REC.    SAE [b](#T4FN2){ref-type="table-fn"}   C.L. [c](#T4FN3){ref-type="table-fn"}   
  ---------------------- ---------------- ---------------- ------- -------------------------------------- --------------------------------------- --------
                                                                                                                                                  
  Intra day assay                                                                                                                                 
    Augmentin -- 625     8.00             7.943 ± 0.048    0.605   99.282                                 0.0215                                  0.0597
    Augmentin -- 625     20.00            19.943 ± 0.087   0.437   99.713                                 0.0390                                  0.1082
    Augmentin -- 625     32.00            31.943 ± 0.104   0.327   99.820                                 0.0467                                  0.1296
    Flemiclav -- 625     8.00             7.966 ± 0.048    0.604   99.569                                 0.0215                                  0.0597
    Flemiclav -- 625     20.00            19.920 ± 0.094   0.474   99.598                                 0.0422                                  0.1172
    Flemiclav -- 625     32.00            31.920 ± 0.135   0.422   99.749                                 0.0603                                  0.1673
    Moxikind -- CV 625   8.00             7.908 ± 0.048    0.608   98.851                                 0.0215                                  0.0597
    Moxikind -- CV 625   20.00            19.908 ± 0.115   0.577   99.540                                 0.0514                                  0.1427
    Moxikind -- CV 625   32.00            31.874 ± 0.160   0.500   99.605                                 0.0713                                  0.1979
    Clavam -- 625        8.00             7.897 ± 0.070    0.891   98.707                                 0.0315                                  0.0874
    Clavam -- 625        20.00            19.874 ± 0.096   0.484   99.368                                 0.0430                                  0.1194
    Clavam -- 625        32.00            31.828 ± 0.210   0.659   99.461                                 0.0937                                  0.2602
  Inter day assay                                                                                                                                 
    Augmentin -- 625     8.00             7.931 ± 0.065    0.826   99.138                                 0.0293                                  0.0814
    Augmentin -- 625     20.00            19.908 ± 0.091   0.457   99.540                                 0.0406                                  0.1128
    Augmentin -- 625     32.00            31.908 ± 0.154   0.483   99.713                                 0.0689                                  0.1915
    Flemiclav -- 625     8.00             7.954 ± 0.058    0.723   99.425                                 0.0257                                  0.0713
    Flemiclav -- 625     20.00            19.851 ± 0.115   0.579   99.253                                 0.0514                                  0.1427
    Flemiclav -- 625     32.00            31.851 ± 0.170   0.532   99.533                                 0.0758                                  0.2104
    Moxikind -- CV 625   8.00             7.919 ± 0.066    0.827   98.994                                 0.0293                                  0.0814
    Moxikind -- CV 625   20.00            19.851 ± 0.147   0.738   99.253                                 0.0655                                  0.0819
    Moxikind -- CV 625   32.00            31.874 ± 0.179   0.562   99.605                                 0.0801                                  0.2222
    Clavam -- 625        8.00             7.919 ± 0.087    1.101   98.994                                 0.0390                                  0.1082
    Clavam -- 625        20.00            19.839 ± 0.131   0.661   99.195                                 0.0586                                  0.0603
    Clavam -- 625        32.00            31.805 ± 0.135   0.424   99.389                                 0.0603                                  0.1673

Mean for 5 independent analyses; SD, standard deviation; RSD, relative standard deviation;

SAE, standard analytical error;

C.L., confidence limit at 95 % confidence level and 4 degrees of freedom (t=2.776).

The proposed method was used for estimating of PC and AT from tablet after spiking with 50, 150, 250 and 100, 300, 500% of additional pure drug respectively. The results are reported in Table [5](#T5){ref-type="table"}. As can be seen from Table [5](#T5){ref-type="table"} that the recovery and RSD values were in the ranges 98.634--99.942%, 0.563--1.120% and 98.966--99.885%, 0.303--1.085% respectively. The selectivity of the propose method was ascertained by analyzing standard PC and AT in the presence tablet such as colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, polydextrose, titanium dioxide. It was observed that the excipients did not interfere with the proposed method.

###### 

Summary of data for the determination of PC and AT in pharmaceutical preparations by standard addition method

  Proposed methods         Amount (μg/ml)   Recovery (%)   RSD (%)          SAE [b](#T5FN2){ref-type="table-fn"}           
  ------------------------ ---------------- -------------- ---------------- -------------------------------------- ------- --------
                                                                                                                           
    Augmentin 625          2.00             1.00           2.998 ± 0.020    99.942                                 0.661   0.0089
                           2.00             3.00           4.970 ± 0.040    99.409                                 0.798   0.0177
                           2.00             5.00           6.991 ± 0.055    99.878                                 0.787   0.0245
    Flemiclav 625          2.00             1.00           2.991 ± 0.033    99.710                                 1.088   0.0146
                           2.00             3.00           4.964 ± 0.052    99.269                                 1.039   0.0231
                           2.00             5.00           6.915 ± 0.061    98.783                                 0.882   0.0757
    Moxikind CV 625        2.00             1.00           2.995 ± 0.026    99.826                                 0.861   0.0115
                           2.00             3.00           4.974 ± 0.043    99.478                                 0.856   0.0191
                           2.00             5.00           6.928 ± 0.063    98.981                                 0.915   0.0284
    Clavam 625             2.00             1.00           2.988 ± 0.033    99.594                                 1.120   0.0150
                           2.00             3.00           4.960 ± 0.040    99.200                                 0.799   0.0177
                           2.00             5.00           6.904 ± 0.039    98.634                                 0.563   0.0174
  Amoxicillin Trihydrate                                                                                                   
    Augmentin 625          5.00             5.00           9.954 ± 0.075    99.540                                 0.753   0.0335
                           5.00             15.00          19.897 ± 0.110   99.483                                 0.556   0.0494
                           5.00             25.00          29.966 ± 0.091   99.885                                 0.303   0.0406
    Flemiclav 625          5.00             5.00           9.943 ± 0.087    99.425                                 0.877   0.0390
                           5.00             15.00          19.862 ± 0.125   99.310                                 0.627   0.0557
                           5.00             25.00          29.954 ± 0.111   99.847                                 0.369   0.0494
    Moxikind CV 625        5.00             5.00           9.908 ± 0.108    99.080                                 1.085   0.0481
                           5.00             15.00          19.839 ± 0.094   99.195                                 0.476   0.0422
                           5.00             25.00          29.943 ± 0.132   99.808                                 0.442   0.0592
    Clavam 625             5.00             5.00           9.896 ± 0.075    98.966                                 0.757   0.0335
                           5.00             15.00          19.816 ± 0.066   99.081                                 0.331   0.0293
                           5.00             25.00          29.920 ± 0.137   99.732                                 0.459   0.0614

Mean for 5 independent analyses;

SAE, standard analytical error; RSD, relative standard deviation.

The performance of the proposed method was studied with other existing HPLC method ([@R5]). In this case, the Standard Deviation (SD) and Relative Standard Deviation (RSD) values of the proposed method is much better as compared to reported method (Table [6](#T6){ref-type="table"}) and the method is not applied for invitro determination of PC and AT in human urine samples. The method is also applied to measure the concentration of other antibiotics such as ticarcilin.

###### 

Assay results of PC and AT in commercial tablet using the proposed and reference method ([@R5])

  Method                   Recovery (%)   SD (%)   RSD (%)
  ------------------------ -------------- -------- ---------
                                                   
  Potassium Clavulanate                            
    Proposed               99.61           0.033    0.007
    Reference              103.04          2.12     0.412
  Amoxycillin Trihydrate                           
    Proposed               99.82           0.104    0.0008
    Reference              102.58          1.18     0.920

SD, standard deviation; RSD, relative standard deviation.

Approximately 50 % to 70 % of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of a single amoxicillin and clavulanate potassium tablet 500 mg/125 mg. The results are accurate for healthy controls (Table [7](#T7){ref-type="table"}). The usual adult dose is one 500 mg tablet of amoxicillin/clavulanate potassium every 12 hours or one 250 mg tablet of amoxicillin/clavulanate potassium every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one 875 mg tablet of amoxicillin/clavulanate potassium every 12 hours or one 500 mg tablet of amoxicillin/clavulanate potassium every 8 hours.

###### 

Application of the proposed UV method to the determination of PC and AT in human urine samples

  Amount added (μg/ml)     Amount found (μg/ml)   Recovery (%)
  ------------------------ ---------------------- --------------
                                                  
  Potassium Clavulanate                           
  1.00                     0.9624                 96.240
  2.00                     1.9581                 97.905
  3.00                     2.9541                 98.470
  4.00                     3.9701                 99.253
  5.00                     4.9860                 99.720
  6.00                     5.9512                 99.187
  7.00                     6.9874                 99.820
  8.00                     7.9745                 99.681
  X                                               98.785
  RSD                                             1.239
  Amoxicillin Trihydrate                          
  9.00                      8.7841                97.601
  12.00                    11.7810                98.175
  15.00                    14.8125                98.750
  18.00                    17.8712                99.284
  21.00                    20.8914                99.483
  24.00                    23.9062                99.609
  27.00                    26.8950                99.611
  30.00                    29.8812                99.604
  X                                               99.015
  RSD                                             0.775

RSD, relative standard deviation.

Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Severely impaired patients with a glomerular filtration rate of \<30 mL/min. should not receive the 875 mg tablet. Patients with a glomerular filtration rate of 10 to 30 mL/min. should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection. Patients with a less than 10 mL/min. glomerular filtration rate should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection.

Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis. Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals. Urine pH is used to classify urine as either a dilute acid or base solution. Seven is the point of neutrality on the pH scale. The lower the pH, the greater the acidity of a solution; the higher the pH, the greater the alkalinity. The glomerular filtrate of blood is usually acidified by the kidneys from a pH of approximately 7.4 to a pH of about 6 in the urine. Depending on the person's acid-base status, the pH of urine may range from 4.5 to 8. The kidneys maintain normal acid-base balance primarily through the reabsorption of sodium and the tubular secretion of hydrogen and ammonium ions. Urine becomes increasingly acidic as the amount of sodium and excess acid retained by the body increases. Alkaline urine, usually containing bicarbonate-carbonic acid buffer, is normally excreted when there is an excess of base or alkali in the body. Secretion of an acid or alkaline urine by the kidneys is one of the most important mechanisms the body uses to maintain a constant body pH.

The formation of renal stones is related to the urine pH. Patients being treated for renal calculi are frequently given diets or medications to change the pH of the urine so that kidney stones will not form. Calcium phosphate, calcium carbonate, and magnesium phosphate stones develop in alkaline urine; when this occurs, the urine is kept acidic. Uric acid, cystine, and calcium oxalate stones precipitate in acidic urine; in this situation, the urine should be kept alkaline or less acidic than normal. This method is suitable for determination PC and AT in urine samples with different pH (8 μg/ml) and having foreign bodies likes crystals and stones. The results (Table [8](#T8){ref-type="table"} & [9](#T9){ref-type="table"}) are satisfactorily accurate and precise.

###### 

Application of the proposed method to the determination of PC and AT in urine samples with different pH

  pH                       Amount found (μg/ml)   Recovery (%)   RSD (%)
  ------------------------ ---------------------- -------------- ---------
                                                                 
  Potassium Clavulanate                                          
    4.50                   7.510                  93.88          2.05
    5.00                   7.546                  94.33          1.89
    5.50                   7.559                  94.49          1.79
    6.00                   7.690                  96.13          1.70
    7.00                   7.792                  97.40          1.60
    7.5                    7.531                  94.12          1.97
    8.00                   7.068                  88.35          2.11
  Amoxicillin Trihydrate                                         
    4.50                   7.470                  92.10          1.99
    5.50                   7.516                  93.25          1.78
    6.00                   7.539                  94.10          1.65
    6.50                   7.621                  95.03          1.58
    7.00                   7.812                  98.40          1.50
    7.50                   7.561                  93.12          1.80
    8.00                   7.552                  94.02          1.90

RSD, relative standard deviation

###### 

Application of the proposed method to the determination of PC and AT in human urine samples with the presence of foreign bodies

  Amount added (μg/ml)     Amount found (μg/ml)   Recovery (%)
  ------------------------ ---------------------- --------------
                                                  
  Potassium Clavulanate                           
  1.00                      0.9420                94.20
  2.00                      1.9181                95.91
  3.00                      2.8841                96.14
  4.00                      3.9201                98.00
  5.00                      4.9060                98.12
  X                                               96.47
  RSD                                             1.690
  Amoxicillin Trihydrate                           
  8.00                      7.7283                96.60
  10.00                     9.7810                97.81
  12.00                    11.8720                98.93
  14.00                    13.4221                95.87
  16.00                    15.4702                95.69
  X                                               96.98
  RSD                                             1.41

RSD, relative standard deviation.

CONCLUSIONS
===========

The proposed method does not require any laborious clean up procedure before measurement. In addition, the method has wider linear dynamic range with good accuracy and precision. The method shows no interference from the common excipients and additives. This method is simple, cost affective, fast and efficient method. This may help in analyzing affectivity of this drug in human beings during treatment. Therefore, it is concluded that the proposed method is simple, sensitive and rapid for the determination of potassium clavulanate and amoxicillin trihydrate in bulk, pharmaceutical formulations and in human urine samples.
